JPH07102113B2 - Slimming food - Google Patents
Slimming foodInfo
- Publication number
- JPH07102113B2 JPH07102113B2 JP4333575A JP33357592A JPH07102113B2 JP H07102113 B2 JPH07102113 B2 JP H07102113B2 JP 4333575 A JP4333575 A JP 4333575A JP 33357592 A JP33357592 A JP 33357592A JP H07102113 B2 JPH07102113 B2 JP H07102113B2
- Authority
- JP
- Japan
- Prior art keywords
- weight
- cyclodextrin
- parts
- linolenic acid
- branched
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 235000013305 food Nutrition 0.000 title claims description 15
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims description 26
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims description 26
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims description 26
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 24
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 claims description 17
- 229960002733 gamolenic acid Drugs 0.000 claims description 17
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 claims description 16
- 235000020664 gamma-linolenic acid Nutrition 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000002195 synergetic effect Effects 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 208000008589 Obesity Diseases 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 235000020824 obesity Nutrition 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229940100445 wheat starch Drugs 0.000 description 5
- 239000000463 material Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000004584 weight gain Effects 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- 239000001116 FEMA 4028 Substances 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 3
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 3
- 229960004853 betadex Drugs 0.000 description 3
- 229940097362 cyclodextrins Drugs 0.000 description 3
- 235000008524 evening primrose extract Nutrition 0.000 description 3
- 229940089020 evening primrose oil Drugs 0.000 description 3
- 239000010475 evening primrose oil Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
Description
【０００１】[0001]
【産業上の利用分野】本発明は痩身用食品に関する。FIELD OF THE INVENTION The present invention relates to a slimming food.
【０００２】[0002]
【従来の技術】サイクロデキストリンにはその分子構造
上の差異から３種の化合物が存在し、更に詳しくはα−
サイクロデキストリン、β−サイクロデキストリン並び
にγ−サイクロデキストリンの３種の化合物が存在す
る。これ等サイクロデキストリンは古くから食品用の素
材として使用されて来ており、特にβ−サイクロデキス
トリンはその包接作用に基づく各種の用途、たとえば味
覚改良材や粉末アルコール等に利用されている。しかし
ながらこのβ−サイクロデキストリンは消化性物質で人
体の小腸から吸収されるために栄養過多となる傾向があ
り、痩身用食品の素材としては極めて不向きなものであ
る。BACKGROUND OF THE INVENTION Cyclodextrins have three types of compounds due to differences in their molecular structures. More specifically, α-
There are three compounds, cyclodextrin, β-cyclodextrin and γ-cyclodextrin. These cyclodextrins have been used as a material for foods for a long time, and particularly β-cyclodextrin has been used for various purposes based on its clathrate action, such as taste improver and powdered alcohol. However, since β-cyclodextrin is a digestive substance and is absorbed from the small intestine of the human body, it tends to be overnourished, which makes it extremely unsuitable as a material for slimming foods.
【０００３】而して最近サイクロデキストリンの１種た
るα−サイクロデキストリンは人の消化酵素によっては
消化され難い性質を有することが見出され、痩身用食品
の素材として使用出来る可能性のあることが発表され
た。そして引き続きこのα−サイクロデキストリンが消
化器官内にて特異選択的に遊離脂肪酸を吸着し排泄する
作用を有することも見出されるに至った。Recently, α-cyclodextrin, which is one of cyclodextrins, has been found to be difficult to be digested by human digestive enzymes, and may be used as a material for slimming foods. Was announced. Then, it has also been found that this α-cyclodextrin has a function of specifically adsorbing and excreting free fatty acids in the digestive organs.
【０００４】一方γ−リノレン酸は脂肪代謝作用を有す
る物質として古くから良く知られており、その他たとえ
ばコレステロール値と血圧の調整等にも有効である等各
種の健康維持に好適な物質として知られている。On the other hand, γ-linolenic acid has long been well known as a substance having a fat-metabolizing action, and is also known as a substance suitable for maintaining various health such as being effective for adjusting cholesterol level and blood pressure. ing.
【０００５】また一方分子量の大きい蛋白質分子を加水
分子し低分子化したものには多彩な生理作用と複雑なる
作用機構のあることが見出され、活性機能性ペプチドと
しての位置づけが成されている。On the other hand, it has been found that a protein molecule having a large molecular weight hydrolyzed into a low molecular weight molecule has various physiological functions and a complicated mechanism of action, and is positioned as an active functional peptide. .
【０００６】[0006]
【発明の目的並びに概要】本発明者は従来から痩身用食
品について研究を続けて来たが、この研究に於いて各種
の肥満防止に有効な数多くの化合物のうち、特にα−サ
イクロデキストリンとγ−リノレン酸とを併用する場合
は、これ等の相乗作用により著しく優れた肥満乃至体重
増加防止効果を発揮することを見出し、痩身用食品とし
て極めて好適なものであることを確認し、これに基づく
発明を出願し、特許された。更に引き続く研究に於い
て、α−サイクロデキストリンに代えて、分岐のα−サ
イクロデキストリンを使用し、且つγ−リノレン酸と活
性機能性ペプチドとを併用するときは、これ等三者の相
乗作用によって、肥満防止効果が、さらに著しく向上す
ることを見出し、本発明を完成した。OBJECT AND SUMMARY OF THE INVENTION The present inventor has been researching slimming foods for a long time. In this research, among many compounds effective for preventing obesity, α-cyclodextrin and γ are particularly preferable. -When used in combination with linolenic acid, it was found that the synergistic effect of these exerts a remarkable effect of preventing obesity or weight gain, and confirmed that it is extremely suitable as a slimming food, and based on this He filed and patented an invention. In a subsequent study, when branched α-cyclodextrin was used instead of α-cyclodextrin, and when γ-linolenic acid and an active functional peptide were used in combination, the synergistic action of these three factors was observed. The inventors have found that the effect of preventing obesity is further significantly improved, and completed the present invention.
【０００７】[0007]
【発明の構成】本発明の痩身用食品は、分岐のα−サイ
クロデキストリン、γ−リノレン酸及び活性機能性ペプ
チドとを、好ましくは上記デキストリン１００重量部に
対してγ−リノレン酸０.５〜５０重量部及びペプチド
１０〜１０００重量部、特に好ましくはリノレン酸３〜
４重量部及びペプチド４００〜６００重量部含有して成
るものである。The slimming food of the present invention comprises a branched α-cyclodextrin, γ-linolenic acid and an active functional peptide, preferably 0.5-γ-linolenic acid based on 100 parts by weight of the dextrin. 50 parts by weight and peptides 10 to 1000 parts by weight, particularly preferably linolenic acid 3 to
4 parts by weight and 400 to 600 parts by weight of the peptide.
【０００８】本発明に於いて使用される分岐のα−サイ
クロデキストリンとしては、従来から知られているもの
がいずれも使用出来る。この分岐のα−サイクロデキス
トリンは、これを単独で使用しても良く、またこれを含
有する素材を使用しても良い。また非分岐のα−サイク
ロデキストリンとの併用も可能であり、この場合非分岐
のα−サイクロデキストリンの比率は重量比で０〜４５
％が適当である。As the branched α-cyclodextrin used in the present invention, any conventionally known one can be used. This branched α-cyclodextrin may be used alone, or a material containing it may be used. Further, it can be used in combination with unbranched α-cyclodextrin, in which case the ratio of unbranched α-cyclodextrin is 0 to 45 by weight.
% Is appropriate.
【０００９】本発明に於いて使用されるγ−リノレン酸
としてもこれを単独で使用しても良く、またこれを含有
する成分乃至物質たとえば月見草油等を使用しても良
い。The .gamma.-linolenic acid used in the present invention may be used alone, or a component or substance containing the same such as evening primrose oil may be used.
【００１０】本発明に於いて使用する活性機能性ペプチ
ドとは、ポリペプチドを通常の方法により加水分解した
ものをいい、これ自体は公知のものである。活性とは低
分子化することにより蛋白質としての性質に加え、元の
蛋白質には見出せない新しい特性が加わることをいい、
機能性とは、ペプチド本来の各種作用をそのまま保持し
ていることを示す。この活性機能性ペプチドは、当業界
では活性という言葉を省略して、単に機能性ペプチドと
も称されるものである。何れに於いてもポリペプチドを
通常の方法で加水分解したものである。ペプチドとして
は、そのアミノ酸鎖長は７〜１２程度好ましくは８〜１
０程度のものである。The active functional peptide used in the present invention is a polypeptide obtained by hydrolyzing a polypeptide by a usual method, which is a known substance per se. Activity means adding a new property not found in the original protein in addition to the property as a protein by reducing the molecular weight,
The term "functionality" means that the various actions inherent to the peptide are retained as they are. This active functional peptide is
Then, omitting the word “active”,
Is also called. In either case
It is hydrolyzed by a usual method. The peptide has an amino acid chain length of about 7 to 12, preferably 8 to 1.
It is about 0.
【００１１】本発明に於いては上記３種類の化合物を併
用することを必須とし、これ等三者の相乗作用により、
著しく優れた肥満防止乃至体重増加防止効果を発揮す
る。この相乗作用は特に分岐のα−サイクロデキストリ
ン１００重量部に対しγ−リノレン酸０.５〜５０重量
部特に好ましくは３〜２５重量部、ペプチド１０〜１０
００重量部特に好ましくは４００〜６００重量部の割合
で発揮される。この優れた相乗作用は後記実験例からも
極めて明らかである。In the present invention, it is essential to use the above-mentioned three kinds of compounds in combination, and due to the synergistic action of these three compounds,
It exerts a remarkable effect of preventing obesity and weight gain. This synergistic effect is especially 0.5 to 50 parts by weight of γ-linolenic acid based on 100 parts by weight of branched α-cyclodextrin, particularly preferably 3 to 25 parts by weight, peptides 10 to 10 parts by weight.
00 parts by weight, particularly preferably 400 to 600 parts by weight. This excellent synergistic effect is extremely clear from the experimental examples described below.
【００１２】本発明に於いては、上記三成分を所定の割
合で各種の食品または食品添加材に含有させるか、また
はこれ等両者を必要に応じ従来公知の各種の添加材と共
に適当な形状、たとえば錠剤、丸剤、顆粒状に成型して
も良い。含有させるべき食品乃至食品添加材としても特
に限定されず、各種のものが広い範囲で使用出来、たと
えば小麦粉、食物繊維素、大豆粉等を具体例として例示
出来る。また錠剤、丸剤、顆粒状に賦形する際に使用さ
れる添加材としても、従来からこの種分野に於いて使用
されて来たものがいずれも使用出来、たとえば乳糖、ブ
ドウ糖、澱粉等を具体例として挙げることが出来る。In the present invention, the above-mentioned three components are contained in various foods or food additives at a predetermined ratio, or both of them are added together with various conventionally known additives in appropriate shapes, if necessary. For example, it may be molded into tablets, pills, or granules. The food or food additive to be contained is not particularly limited, and various kinds can be used in a wide range, and wheat flour, dietary fibrin, soybean flour and the like can be exemplified as specific examples. Also, as tablets, pills, and additives used when shaping into granules, any of those conventionally used in this kind of field can be used, such as lactose, glucose, starch and the like. It can be mentioned as a specific example.
【００１３】以下に本発明の相乗効果をより明瞭にする
ための実験例と本発明の具体例たる実施例を示す。Experimental examples for further clarifying the synergistic effect of the present invention and practical examples of the present invention will be shown below.
【００１４】[0014]
【実験例】４週令の雄ラットを、その平均体重が１４０
gとなるように６つの群に分け、夫々の群につき６匹ず
つのラットに、次の割合にて調製した飼料を夫々対応す
る群に１日１回、２.０g／kgずつ胃内投与し、それ以外
は同一の市販固型飼料を自由に摂取させて飼育し、１０
日後、２０日後、３０日後の各群ラットの平均体重を求
め、その体重増加抑制効果を測定した。但し飼料６はコ
ントロールである。[Experimental example] Male rats aged 4 weeks had an average weight of 140
The rats were divided into 6 groups to achieve g, and 6 rats in each group were intragastrically administered with 2.0 g / kg of the feed prepared at the following ratio once to each corresponding group once a day. However, other than that, the same commercially available solid feed was freely ingested and raised.
The average body weight of the rats in each group after 20 days and 30 days was determined, and the effect of suppressing the weight gain was measured. However, feed 6 is a control.
【００１５】 飼料１：分岐のα−サイクロデキストリン・・・・・・ ５０mg γ−リノレン酸・・・・・・・・・・・・・・・・・・・・・・ ０mg 活性機能性ペプチド・・・・・・・・・・・・・・・・・・ ０mg 小麦澱粉・・・・・・・・・・・・・・・・・・・・・・・・・・・・５０５mgFeed 1: branched α-cyclodextrin: 50 mg γ-linolenic acid: 0 mg Active functional peptide・ ・ ・ ・ 0 mg Wheat Starch ・ ・ ・ ・ ・ ・ ・ ・ ・ 505 mg
【００１６】 飼料２：分岐のα−サイクロデキストリン・・・・・・ ０mg γ−リノレン酸・・・・・・・・・・・・・・・・・・・・・・ ５mg 活性機能性ペプチド・・・・・・・・・・・・・・・・・・ ０mg 小麦澱粉・・・・・・・・・・・・・・・・・・・・・・・・・・・・５５０mgFeed 2: Branched α-cyclodextrin: 0 mg γ-linolenic acid: 5 mg Active functional peptide・ ・ ・ ・ 0mg Wheat Starch ・ ・ ・ ・ ・ ・ ・ ・ ・ 550mg
【００１７】 飼料３：分岐のα−サイクロデキストリン・・・・・・ ０mg γ−リノレン酸・・・・・・・・・・・・・・・・・・・・・・ ０mg 活性機能性ペプチド・・・・・・・・・・・・・・・・・・５００mg 小麦澱粉・・・・・・・・・・・・・・・・・・・・・・・・・・・・ ５５mgFeed 3: Branched α-cyclodextrin: 0 mg γ-linolenic acid: 0 mg Active functional peptide・ ・ ・ ・ 500mg Wheat starch ・ ・ ・ ・ ・ ・ ・ ・ ・ 55mg
【００１８】 飼料４：分岐のα−サイクロデキストリン・・・・・・ ５０mg γ−リノレン酸・・・・・・・・・・・・・・・・・・・・・・ ５mg 活性機能性ペプチド・・・・・・・・・・・・・・・・・・５００mg 小麦澱粉・・・・・・・・・・・・・・・・・・・・・・・・・・・・ ０mgFeed 4: Branched α-cyclodextrin: 50 mg γ-linolenic acid: 5 mg Active functional peptide・ ・ ・ ・ 500mg Wheat starch ・ ・ ・ ・ ・ ・ ・ ・ ・ 0mg
【００１９】 飼料５：分岐のα−サイクロデキストリン・・・・・・ ０mg γ−リノレン酸・・・・・・・・・・・・・・・・・・・・・・ ５mg 活性機能性ペプチド・・・・・・・・・・・・・・・・・・５００mg 小麦澱粉・・・・・・・・・・・・・・・・・・・・・・・・・・・・ ０mg α−サイクロデキストリン・・・・・・・・・・・・ ５０mgFeed 5: branched α-cyclodextrin: 0 mg γ-linolenic acid: 5 mg Active functional peptide ····················································· α-Cyclodextrin: 50 mg
【００２０】 飼料６：分岐のα−サイクロデキストリン・・・・・・ ０mg γ−リノレン酸・・・・・・・・・・・・・・・・・・・・・・ ０mg 活性機能性ペプチド・・・・・・・・・・・・・・・・・・ ０mg 小麦澱粉・・・・・・・・・・・・・・・・・・・・・・・・・・・・５５５mgFeed 6: Branched α-cyclodextrin: 0 mg γ-linolenic acid: 0 mg Active functional peptide・ ・ ・ ・ 0mg Wheat Starch ・ ・ ・ ・ ・ ・ ・ ・ ・ 555mg
【００２１】この結果を下記表１〜３に示す。但し表中
数値はgを表す。The results are shown in Tables 1 to 3 below. However, the numerical values in the table represent g.
【００２２】[0022]
【表１】 [Table 1]
【００２３】但し表１は各群ラットの平均体重の推移
（g）を示す。However, Table 1 shows the transition (g) of the average body weight of each group of rats.
【００２４】[0024]
【表２】 [Table 2]
【００２５】但し表２は各群ラットのコントロールとの
平均体重差（g）、即ち対コントロール群を示す。However, Table 2 shows the average body weight difference (g) from the control of each group of rats, that is, the control group.
【００２６】[0026]
【表３】 [Table 3]
【００２７】但し表３は各群ラットの体重増減率（各群
の平均体重／コントロール群の平均体重）を示す。However, Table 3 shows the rate of increase or decrease in the weight of the rats in each group (average weight of each group / average weight of the control group).
【００２８】以上の結果から分岐のα−サイクロデキス
トリン、γ−リノレン酸及び活性機能性ペプチドを夫々
単独で使用した第１群〜第３群は、コントロールの第６
群に比べて体重は減少しているものの、その低下率は小
さく、これに対して三者を併用した第４群では大きく体
重増加抑制効果が認められ、１０日後、２０日後、３０
日後のいずれに於いてもその相乗効果は極めて明らかで
ある。また分岐のα−サイクロデキストリンを使用せ
ず、α−サイクロデキストリンを使用した第５群では第
４群に比しその体重増加抑制効果はいずれも低下してい
る。From the above results, the groups 1 to 3 in which the branched α-cyclodextrin, γ-linolenic acid and the active functional peptide were used alone were the control 6th group.
Although the body weight was reduced compared to the group, the rate of decrease was small, whereas a large effect of suppressing weight gain was observed in group 4 in which the three were combined, and after 10 days, 20 days, 30 days
The synergistic effect is extremely clear after any day. In addition, in the fifth group using α-cyclodextrin without using branched α-cyclodextrin, the effect of suppressing body weight increase is lower than that in the fourth group.
【００２９】[0029]
【００３０】[0030]
【実施例１】分岐のα−サイクロデキストリン２０重量
部、γ−リノレン酸９重量％を含む月見草油１０重量部
及びペプチド１００重量部を、乳糖１００重量部に配合
し顆粒剤として痩身用食品を調製した。Example 1 20 parts by weight of branched α-cyclodextrin, 10 parts by weight of evening primrose oil containing 9% by weight of γ-linolenic acid, and 100 parts by weight of peptide were added to 100 parts by weight of lactose to prepare a slimming food as granules. Prepared.
【００３１】[0031]
【実施例２】分岐のα−サイクロデキストリン３０重量
部、γ−リノレン酸９重量％を含む月見草油１０重量部
及びペプチド１００重量部を、乳糖、ブドウ糖並びに天
然果汁粉末と共に混合し、常法に従って錠剤となした。Example 2 30 parts by weight of branched α-cyclodextrin, 10 parts by weight of evening primrose oil containing 9% by weight of γ-linolenic acid and 100 parts by weight of peptide were mixed with lactose, glucose and natural juice powder, and the mixture was mixed according to a conventional method. Made into tablets.
【００３２】[0032]
【発明の効果】本発明の痩身用食品に於いては、分岐の
α−サイクロデキストリン、γ−リノレン酸及び活性機
能性ペプチドの三者を含有しているので、これ等三者の
相乗作用により、著しく優れた肥満防止または体重防止
効果を発揮する。このため痩身用として極めて優れた食
品となり、肥満または体重過剰に基づく各種疾病の予防
に極めて有効である。INDUSTRIAL APPLICABILITY The slimming food of the present invention contains the branched α-cyclodextrin, γ-linolenic acid, and the active functional peptide, so that the synergistic action of these three causes , Remarkably excellent obesity prevention or body weight prevention effect. Therefore, it becomes an excellent food for slimming and is extremely effective in preventing various diseases caused by obesity or overweight.
Claims (2)
ノレン酸及び活性機能性ペプチドとを含有して成る痩身
用食品。1. A slimming food comprising a branched α-cyclodextrin, γ-linolenic acid and an active functional peptide.
量部に対して、γ−リノレン酸が０.５〜１０重量部及
び上記ペプチドが１０〜１０００重量部の割合で含有さ
れて成る請求項１に記載の痩身用食品。2. The method according to claim 1, wherein 0.5 to 10 parts by weight of γ-linolenic acid and 10 to 1000 parts by weight of the peptide are contained in 100 parts by weight of branched α-cyclodextrin. The slimming food described.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4333575A JPH07102113B2 (en) | 1992-11-18 | 1992-11-18 | Slimming food |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4333575A JPH07102113B2 (en) | 1992-11-18 | 1992-11-18 | Slimming food |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH06153861A JPH06153861A (en) | 1994-06-03 |
| JPH07102113B2 true JPH07102113B2 (en) | 1995-11-08 |
Family
ID=18267582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4333575A Expired - Fee Related JPH07102113B2 (en) | 1992-11-18 | 1992-11-18 | Slimming food |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH07102113B2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL220776B1 (en) | 2002-08-19 | 2016-01-29 | Soho Flordis Internat Pty Ltd | The use of α-cyclodextrin for the manufacture of a medicament for reducing diarrhea |
| EP1657114B1 (en) | 2004-11-15 | 2012-01-04 | Harman Becker Automotive Systems GmbH | Navigation device of a vehicle and memory unit mounting system |
| JP4939788B2 (en) * | 2005-10-04 | 2012-05-30 | カルピス株式会社 | Peptide-containing food and drink with reduced bitterness and astringency and method for producing the same |
-
1992
- 1992-11-18 JP JP4333575A patent/JPH07102113B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH06153861A (en) | 1994-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0492235B1 (en) | Low moisture cholestyramine composition | |
| JP4615812B2 (en) | Composition containing peptide and electrolyte excretion promoting substance and food containing the same | |
| JP3001880B1 (en) | Foods containing wheat leaves | |
| TWI409037B (en) | Induced-viscosity nutritional emulsions | |
| JP2014037422A (en) | Use of water-soluble cellulose derivative for prevention or treatment of metabolic syndrome | |
| JP2010018522A (en) | Adiponectin production enhancer | |
| JPH07102113B2 (en) | Slimming food | |
| JPH0764884B2 (en) | Cyclodextrin composition | |
| JPS6094912A (en) | Body neutral fat reducing agent | |
| JPH06153860A (en) | Flesh-reducing food | |
| JPH07115934A (en) | Diet food | |
| JPS6244905B2 (en) | ||
| JP2978332B2 (en) | Intestinal metabolism improving food and intestinal metabolism improving agent | |
| JPH10179086A (en) | Oil solubilized solution, food and drink containing plant sterol, and method for producing the same | |
| JP3698738B2 (en) | Iron absorption promoter containing guar gum enzyme degradation product as an active ingredient | |
| JP2008156344A (en) | In vivo antioxidant material, in vivo antioxidant food composition and in vivo antioxidant pharmaceutical composition, liver dysfunction inhibitor, liver dysfunction food composition, and liver dysfunction pharmaceutical composition | |
| JP2510943B2 (en) | Slimming food | |
| JP2006273840A (en) | Rice protein composition and use thereof | |
| JPH06205653A (en) | Mineral sorption promotor containing lactulose oligosaccharide as active ingredient | |
| JP2978581B2 (en) | Cholesterol suppressant | |
| JPH11147828A (en) | Cholesterol and lipid absorption inhibitors | |
| JP3512552B2 (en) | Arteriosclerosis inhibitor and food or medicine containing it | |
| JP2006151952A (en) | Hyperlipidemia or hyperuricemia improving agent and health food | |
| JP2605208B2 (en) | Slimming food | |
| US6087345A (en) | Material inhibiting lipid peroxide-increase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101108 Year of fee payment: 15 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121108 Year of fee payment: 17 |
|
| LAPS | Cancellation because of no payment of annual fees |